WO2009128918A8 - Combination therapy using a soluble hyaluronidase and a bisphosphonate - Google Patents
Combination therapy using a soluble hyaluronidase and a bisphosphonate Download PDFInfo
- Publication number
- WO2009128918A8 WO2009128918A8 PCT/US2009/002353 US2009002353W WO2009128918A8 WO 2009128918 A8 WO2009128918 A8 WO 2009128918A8 US 2009002353 W US2009002353 W US 2009002353W WO 2009128918 A8 WO2009128918 A8 WO 2009128918A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bisphosphonate
- soluble hyaluronidase
- combination therapy
- same
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Provided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate- treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same bisphosphonate-treatable disease or condition.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12427708P | 2008-04-14 | 2008-04-14 | |
US61/124,277 | 2008-04-14 | ||
US12433008P | 2008-04-15 | 2008-04-15 | |
US61/124,330 | 2008-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009128918A1 WO2009128918A1 (en) | 2009-10-22 |
WO2009128918A8 true WO2009128918A8 (en) | 2010-04-22 |
Family
ID=41008998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/002353 WO2009128918A1 (en) | 2008-04-14 | 2009-04-14 | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
Country Status (2)
Country | Link |
---|---|
US (1) | US20090311237A1 (en) |
WO (1) | WO2009128918A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10286044B2 (en) | 2003-03-05 | 2019-05-14 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1636248A4 (en) | 2002-12-16 | 2006-09-06 | Halozyme Inc | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US7676953B2 (en) * | 2006-12-29 | 2010-03-16 | Signature Control Systems, Inc. | Calibration and metering methods for wood kiln moisture measurement |
EP3760715B1 (en) * | 2008-03-06 | 2021-08-04 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
TWI489994B (en) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
CA3096629A1 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
SG172064A1 (en) | 2008-12-09 | 2011-07-28 | Halozyme Inc | Extended soluble ph20 polypeptides and uses thereof |
US20100305500A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
AR075721A1 (en) * | 2010-03-05 | 2011-04-20 | Eriochem Sa | PHARMACEUTICAL COMPOSITION THAT INCLUDES A ZOLEDRONIC ACID SOLUTION. |
CA2806058C (en) | 2010-07-20 | 2016-09-13 | Halozyme, Inc. | Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
TWI577377B (en) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | Pharmaceutical compositions |
US10188733B2 (en) | 2010-10-22 | 2019-01-29 | President And Fellows Of Harvard College | Vaccines comprising bisphosphonate and methods of use thereof |
ES2770575T3 (en) | 2010-10-28 | 2020-07-02 | Pacira Pharmaceuticals Inc | Sustained-release formulation of a non-steroidal anti-inflammatory drug |
US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
US9950082B2 (en) * | 2013-04-04 | 2018-04-24 | The Governors Of The University Of Alberta | Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same |
TW201534726A (en) | 2013-07-03 | 2015-09-16 | Halozyme Inc | Thermally stable PH20 hyaluronidase variants and uses thereof |
EP3328378A4 (en) * | 2015-07-30 | 2019-06-05 | Cedars-Sinai Medical Center | Compositions and methods for treating acne |
CN109983013A (en) | 2016-11-18 | 2019-07-05 | 帕西拉制药有限公司 | Meloxicam zinc complexes particle multivesicular liposome preparation and preparation method thereof |
JP2020503365A (en) * | 2017-01-05 | 2020-01-30 | エムビーシー ファーマ, インコーポレイテッド | Drug combination treatment using bone targeted therapeutics for bone disease and bone related diseases |
JP2018115132A (en) * | 2017-01-19 | 2018-07-26 | 国立大学法人岐阜大学 | Promoters for bone fracture healing |
US20210008084A1 (en) | 2017-10-16 | 2021-01-14 | Tsinghua University | Mevalonate pathway inhibitor and pharmaceutical composition thereof |
CA3174498A1 (en) * | 2020-04-02 | 2021-10-07 | Med Progress, LLC | Reducing or inhibiting ocular damage by hyaluronidase administration |
US11890331B2 (en) | 2020-04-02 | 2024-02-06 | Med Progress, LLC | Reducing or inhibiting ocular damage by hyaluronidase administration |
CN116437901A (en) * | 2020-11-17 | 2023-07-14 | 爱尔兰詹森科学公司 | Treatment or prevention of diseases or conditions |
CA3232211A1 (en) * | 2021-09-25 | 2023-03-30 | Med Progress, LLC | Reducing or inhibiting tissue damage using hyaluronidase administration |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6193963B1 (en) * | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
ATE314862T1 (en) * | 2000-05-05 | 2006-02-15 | Hoffmann La Roche | GEL-TYPE PHARMACEUTICAL COMPOSITION FOR SUBCUTANE USE CONTAINING BISPHOSPHONIC ACIDS OR SALTS THEREOF |
JP2004534048A (en) * | 2001-06-05 | 2004-11-11 | メルク エンド カムパニー インコーポレーテッド | Compositions and methods for inhibiting bone resorption |
AU2004218354B2 (en) * | 2003-03-05 | 2009-10-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
DE10361714B4 (en) * | 2003-12-30 | 2009-06-10 | Infineon Technologies Ag | Semiconductor device |
US7572613B2 (en) * | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
-
2009
- 2009-04-14 US US12/386,249 patent/US20090311237A1/en not_active Abandoned
- 2009-04-14 WO PCT/US2009/002353 patent/WO2009128918A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10286044B2 (en) | 2003-03-05 | 2019-05-14 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2009128918A1 (en) | 2009-10-22 |
US20090311237A1 (en) | 2009-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009128918A8 (en) | Combination therapy using a soluble hyaluronidase and a bisphosphonate | |
MX339658B (en) | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase. | |
TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
MX2010005631A (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases. | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
MY191349A (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
MX2007009649A (en) | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer. | |
EP2512479A4 (en) | Methods and compositions for treating peripheral vascular disease | |
BRPI0906181A2 (en) | "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment " | |
WO2007143607A3 (en) | Method of treating atrophic vaginitis | |
MX2009008439A (en) | Novel inhibitors hepatitis c virus replication. | |
EA201001698A1 (en) | INSULIN COMPOSITIONS OF SUPERFAST ACTION | |
WO2008124085A3 (en) | Methods of using combinations of mek and jak-2 inhibitors | |
ATE395905T1 (en) | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SOLID DISPERSIONS FOR THE TREATMENT OF CANCER | |
WO2010048087A3 (en) | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone | |
WO2009128917A3 (en) | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | |
NZ702800A (en) | Methods and compositions for cns delivery of heparan n-sulfatase | |
MX2010002392A (en) | Improved brimonidine compositions for treating erythema. | |
MX2019000547A (en) | Stabilized liquid and lyophilized adamts13 formulations. | |
TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
GEP20115342B (en) | New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | |
WO2009134616A3 (en) | Novel inhibitors of hepatitis c virus replication | |
WO2007056236A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09731564 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09731564 Country of ref document: EP Kind code of ref document: A1 |